Animal Biosciences Announces New Canine Clinical Research Evaluating Reversal of Age-Related Signs in Dogs

After five years of development, positive results are seen in old dogs in a rigorous placebo-controlled trial performed at a leading vet school

BOSTON–(BUSINESS WIRE)–Animal Biosciences, Inc., a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.

After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, the study shows the first clinical evidence that it is possible to reverse age-related decline in dogs.

The supplement, formulated as a soft chew, is a combination of an “NAD booster” to mimic fasting, and a molecule that kills “zombie” senescent cells that cause aging. The combination was developed because the effects in vivo were better than the single molecules alone.

The double-blind clinical study conducted at North Carolina State University Veterinary College, in collaboration with Dr. Natasha Olby, a Professor of Neurology and Neurosurgery, has confirmed the effects of the supplement to significantly improve cognitive function. The formulation may have broader effects on frailty, activity, and happiness, as assessed by owners.

“The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Dr. Olby noted. “This rigorous study, which acknowledges the difficulties aging pets and their owners encounter, shows dedication to scientific methods aimed at improving the quality of life for our canine companions.”

Aging has been defined as the chronic dysregulation of gene expression networks over time leading to subsequent deteriorated tissue and organ function causing age-related functional decline. In senior dogs, as in humans, this age-related decline can manifest as cognitive decline, increased frailty and lower engagement. The results of the trial showed positive impacts in all these areas of decline.

Dr. David A. Sinclair, AO, PhD, Professor of Genetics at Harvard Medical School and co-founder of Animal Biosciences stated, “I am very proud of the teams at NCSU and Animal Biosciences, who, after years of collaborative research and a clinical trial, have developed the first supplement proven to reverse aging in dogs.”

Animal Biosciences Inc. is a Boston-based animal health company focused on delaying aging and extending the healthy lifespan of companion animals. Co-founded in 2017 by well-known longevity pioneer, Professor David A. Sinclair of Harvard Medical School, and his brother, Nick Sinclair, CEO, a dedicated dog-lover with experience in the pharmaceutical and food industries, Animal Biosciences is adapting small molecule-based therapies from human health specifically for companion animals and testing them in rigorous clinical trials. The company has a pipeline of additional small molecules and therapies targeting aging in companion animals.

Phone: 646-964-4446

Alpha Cognition – developing novel treatments for neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS).

Alpha Cognition - developing novel treatments for neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis

ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia and as an intranasal formulation for traumatic brain injury.

ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, promotes cell survival, regulates certain inflammatory processes, and plays a significant role in regulating lysosomal function and microglial responses to disease. Its intended use for the treatment of neurodegenerative diseases has been patented by the Company and Alpha-0602 has been granted an Orphan Drug Designation for the treatment of Amyotrophic Lateral Sclerosis by the FDA.

ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from full length progranulin which have therapeutic potential across multiple neurodegenerative diseases. Progranulin is comprised of 7½ Granulin Epithelin Motifs (GEMs). GEMs are important in regulating cell growth, survival, repair, and inflammation. Individual granulin domain peptides are approximately 60 amino acids in length (~7kDa). GEMs are metabolically stable and resistant to proteolysis (long half-life). Evidence suggests that not all GEMs are equally potent at promoting cell survival signaling or reducing proteinopathy, and may compete (e.g., binding to effectors) with active GEMs and effectively decrease their potency. Specific GEM combinations have been shown to be more effective than full length progranulin in promoting Cathepsin D maturation. GEMs have been shown to be important in regulating cell growth, survival, repair, and inflammation. Alpha-0702 and ALPHA-0802 are designed to deliver this with potentially lower toxicity, and greater therapeutic effect.

More info :

Keywords : Alpha Cognition , neurodegenerative diseases , dementia , Alzheimer’s Dementia , Alzheimer Disease , Amyotrophic Lateral Sclerosis , acetylcholinesterase inhibitor , orphan drug , CNS , neuroscience , traumatic brain injury , Granulin Epithelin Motifs , Gene Therapy

Biophytis – therapeutics to slow down the degenerative processes associated with aging

Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19.

Biophytis - therapeutics to slow down the degenerative processes associated with aging

Biophytis SA, founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two proprietary drug candidates into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory. The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and collaborates with scientists at the Institute of Myology, and the Vision Institute

Its lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.

Biophytis also has preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease. Spinal Muscular Atrophy is a rare progressive neurodegenerative disease that robs an individual of the ability to walk, eat and breathe. SMA is the leading genetic cause of death in infants. Symptoms may appear in the first 6 months of life (type 1, the most severe and common), in infancy (types 2 and 3) or in adulthood (type 4, the least common form). SMA affects 1 in 11,000 births in the United States each year, and about 1 in 50 Americans is a genetic carrier.

More info :

Keywords for Biophytis :

neuromuscular diseases, dry age-related macular degeneration, AMD, ophthalmology, infectious diseases, COVID19, Asthma, COPD, small molecule, sarcopenia, Stargardt disease, Duchenne muscular dystrophy , DMD, preclinical stage pharma company, clinical stage pharma company , Spinal Muscular Atrophy , rare diseases , aging

Newron Pharmaceuticals – innovative therapies for Central Nervous System

Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.

Newron Pharmaceuticals – innovative therapies for Central Nervous System

Newron Pharmaceuticals

Continue reading

Cebiotex – drug delivery with electrospun nanofiber technology

Cebiotex offers manufacturing technology and contract research in the field of drug delivery with electrospun nanofiber technology.

Cebiotex – drug delivery with electrospun nanofiber technology


Continue reading

Poietis – 4D Bioprinting

Poietis is a biotech company whose mission is to design, develop and market innovative solutions based on 4D Bioprinting to support Researchers and Physicians in the emergence of personalized medicine.

Poietis – 4D Bioprinting


Continue reading

Bioinvent – antibody drug discovery

BioInvent is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. BioInvent also develops antibody-based drugs in collaboration with partners who finance the development of new drugs and provide BioInvent with the right to milestone payments and royalties on sales.

Bioinvent – antibody drug discovery


Continue reading